Breast Cancer Patient Education Act of 2015

Pub. Law No. 111-148, Patient Protection and Affordable Care Act, matters related to the implementation of breast health education, research and clinical trials; S.1566/H.R.2722, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients; H.R.1600, Patients' Access to Treatment Act, support amending the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure and prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier; H.R.1608, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; S.1170/H.R.2191, Breast Cancer Research Stamp Reauthorization Act, advocate for the reauthorization of the breast cancer research stamp; S.370/H.R.716, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; H.R.1925, Dr. Balazs "Ernie" Bodai Congressional Gold Medal, support the presentation of a congressional gold medal to Dr. Balaz "Ernie" Bodai in recognition of his many outstanding contributions to the nation, including a tireless commitment to breast cancer research; S.1192/H.R.2540, Breast Cancer Patient Education Act, efforts to support creating an educational campaign to inform breast cancer patients anticipating surgery about the availability and coverage of breast reconstruction and prostheses; H.R.6, 21st Century Cures Act, issues related to cancer prevention and research funding; S.620/H.R.1189, Preserving Employee Wellness Programs Act, issues related to the Genetic Information Act of 2008 and workplace wellness programs; S.1926/H.R.3339, Protecting Access to Lifesaving Screenings Act, amends Title XVIII of the Social Security Act to protect coverage for screening mammography; H.R.2846, Planning Actively for Cancer Treatments Act, support coverage of cancer care planning and coordination services; S.91/H.R.4112, Mobile Mammography Promotion Act, issues related to excluding mobile mammography vehicles from the motor fuel excise tax; H.R.3119, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Institutes of Health (NIH), SENATE

Pub. Law No. 111-148, Patient Protection and Affordable Care Act, matters related to the implementation of breast health education, research and clinical trials; S.1566/H.R.2739, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients; H.R.1600, Patients' Access to Treatment Act, support amending the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure and prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier; H.R.1608, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; S.1170/H.R.2191, Breast Cancer Research Stamp Reauthorization Act, advocate for the reauthorization of the breast cancer research stamp; S.370/H.R.716, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; H.R.1925, Dr. Balazs "Ernie" Bodai Congressional Gold Medal, support the presentation of a congressional gold medal to Dr. Balaz "Ernie" Bodai in recognition of his many outstanding contributions to the nation, including a tireless commitment to breast cancer research; S.1192/H.R.2540, Breast Cancer Patient Education Act, efforts to support creating an educational campaign to inform breast cancer patients anticipating surgery about the availability and coverage of breast reconstruction and prostheses; H.R.6, 21st Century Cures Act, issues related to cancer prevention and research funding; S.620/H.R.1189, Preserving Employee Wellness Programs Act, issues related to the Genetic Information Act of 2008 and workplace wellness programs; S.1926/H.R.3339, Protecting Access to Lifesaving Screenings Act, amends Title XVIII of the Social Security Act to protect coverage for screening mammography.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Pub. Law No. 111-148, Patient Protection and Affordable Care Act, matters related to the implementation of breast health education, research and clinical trials; S.1695/H.R.3020, Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, issues related to cancer prevention and research funding; S.1558/H.R.2685, Department of Defense Appropriations Act, issues related to cancer prevention and research funding; S.1566/H.R.2739, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients; H.R.1600, Patients' Access to Treatment Act, support amending the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure and prohibits such a health plan from imposing higher cost-sharing requirements, including co-payment and co-insurance, for specialty drugs than for other prescription drugs in a non-preferred brand drug tier; H.R.1608, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; S.1170/H.R.2191, Breast Cancer Research Stamp Reauthorization Act, advocate for the reauthorization of the breast cancer research stamp; H.R.2722, Breast Cancer Awareness Commemorative Coin Act, support the creation of a breast cancer awareness coin to increase the funding available for breast cancer research; S.370/H.R.716, Breast Density and Mammography Reporting Act, issues related to the information provided to women and doctors on breast density and the potential impact it has on the detection of breast cancer and require the FDA to utilize up to date medical information and direct HHS to focus research on the best screening methods for breast tissue; H.R.1925, Dr. Balazs "Ernie" Bodai Congressional Gold Medal, support the presentation of a congressional gold medal to Dr. Balaz "Ernie" Bodai in recognition of his many outstanding contributions to the nation, including a tireless commitment to breast cancer research; S.1192/H.R.2540, Breast Cancer Patient Education Act, efforts to support creating an educational campaign to inform breast cancer patients anticipating surgery about the availability and coverage of breast reconstruction and prostheses.

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE